Evaluating the effectiveness and cost-effectiveness of British Sign Language Improving Access to Psychological Therapies: an exploratory study

Alys Young,1* Katherine Rogers,1 Linda Davies,2 Mark Pilling,1 Karina Lovell,1 Steve Pilling,3 Rachel Belk,1 Gemma Shields,2 Claire Dodds,1 Malcolm Campbell,1 Catherine Nassimi-Green,1 Deborah Buck2 and Rosemary Oram1

1Division of Nursing, Midwifery and Social Work, Faculty of Biological, Medical and Health Sciences, University of Manchester, Manchester, UK
2Division of Population Health, Health Services Research and Primary Care, Faculty of Biological, Medical and Health Sciences, University of Manchester, Manchester, UK
3Division of Psychology and Language Sciences, Faculty of Brain Sciences, University College London, London, UK

*Corresponding author alys.young@manchester.ac.uk

Declared competing interests of authors: Alys Young sits on an expert reference group convened by the Royal College of Psychiatry and the charitable organisation SignHealth, in order to draw up guidelines for commissioners of primary mental health services for Deaf people. Katherine Rogers is chairperson of the British Society for Mental Health and Deafness. Steve Pilling is in receipt of funding from the National Horizon Scanning Centre to develop care pathways for the Improving Access to Psychological Therapies programme. Rachel Belk works part-time in a NHS clinical role as a genetics counsellor, where she occasionally works with Deaf patients. Claire Dodds works as a freelance British Sign Language/English interpreter, occasionally within health-care settings.

Published August 2017
DOI: 10.3310/hsdr05240

Scientific summary

Evaluating the effectiveness and cost-effectiveness of BSL IAPT
Health Services and Delivery Research 2017; Vol. 5: No. 24
DOI: 10.3310/hsdr05240

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

This exploratory, mixed-methods study is focused on adults who are Deaf, who use British Sign Language (BSL) as their first, preferred or strongest language, and who experience anxiety and/or depression. BSL is a fully grammatical visual language separate from English. Its users (Deaf people) are formally recognised as a cultural–linguistic community in the UK and are distinguished from the larger number of deaf people who use spoken language. Deaf adults experience poorer mental health than the general population and face significant barriers to accessing mental health services. Poor treatment outcomes are related, in part, to late access to preventative and primary mental health services. Improving Access to Psychological Therapies (IAPT) services deliver approved psychological interventions to address anxiety and depressive disorders in primary care settings and follow the National Institute for Health and Care Excellence-approved stepped care model. IAPT has been adapted for Deaf people and delivered by Deaf therapists using BSL in some parts of England (BSL-IAPT). Elsewhere, Deaf people usually access standard IAPT through an interpreter.

This study both carries out preliminary effectiveness and cost-effectiveness evaluations of the two approaches to psychological therapies for Deaf people and lays the groundwork for a potential large-scale study by addressing deficiencies in instrumentation, population profiling and outcome data, service modelling and patient involvement in research design.

A BSL version of this summary is available (https://video.manchester.ac.uk/faculties/edfa2331ca0cd9a14d717cb1d233466f466d585b6746-4dc5-bc89-1d028b441746/).

Objectives

1. To explore the following questions:
   (a) Is BSL-IAPT more effective than standard IAPT for Deaf people with anxiety and/or depression?
   (b) Is any additional benefit from BSL-IAPT worth any additional cost to provide it?

2. To establish relevant BSL versions of assessment tools and methods to answer research questions (a) and (b).

3. To gauge the feasibility of a larger-scale definitive study and inform its future design.

Methods

The acceptability of randomisation and trial-related terminology in British Sign Language

The acceptability of randomisation and trial-related terminology in BSL were explored through four Deaf-led focus groups with Deaf community members (n = 19) who met on two occasions. Participants were aged ≥ 18 years, were BSL users and were not receiving support through the IAPT programme. BSL data were kept in the source language and subjected to a phenomenological approach to qualitative analysis (objective 3).
The clinical cut-off points for the Patient Health Questionnaire-9 item in British Sign Language and Generalised Anxiety Disorder-7 in British Sign Language

The clinical cut-off points for the Patient Health Questionnaire-9 item (PHQ-9) in BSL and Generalised Anxiety Disorder-7 (GAD-7) in BSL were determined through secondary analysis of two data sets. Data set 1 (n = 502) comprised Deaf users of the BSL-IAPT service who met caseness and for whom at least one score on the PHQ-9 BSL and/or GAD-7 BSL had been recorded. Data set 2 (n = 85) comprised Deaf BSL users who were not users of the IAPT, who had no reported mental health difficulties in the past 12 months and who had completed the PHQ-9 BSL and GAD-7 BSL. Parameter estimates, including the area under the curve (AUC) value, sensitivity, positive predicted value and negative predicted value, were used in the calculation of the clinical cut-off points of PHQ-9 BSL and GAD-7 BSL (objectives 1 and 2).

Comparison of Deaf users of BSL-IAPT and standard Improving Access to Psychological Therapies characteristic and clinical outcomes

Secondary data analysis was used to compare routinely recorded client data obtained from standard IAPT services that had provided a service to Deaf individuals (n = 116) with client data and outcomes from the cohort of Deaf people who had used BSL-IAPT (n = 429). Characteristics and outcomes of clients were compared descriptively by IAPT group. Independent sample t-tests were used to compare mean scores for the PHQ-9 and GAD-7 by group. The prevalence of anxiety and/or depression, recovery and reliable recovery were compared by group using Pearson’s chi-squared test; reliable improvement was compared by group using the chi-squared test for trend. Because of their skewness, waiting times were compared by group using the Mann–Whitney U-test (objectives 1 and 3).

Mixed-methods modelling of standard Improving Access to Psychological Therapies services accessed by Deaf people and BSL-IAPT

A sequential mixed-methods study design was used. Initially, self-selecting IAPT practitioners completed a survey consisting of closed and open questions in order to capture a broad range of views and experiences (n = 118). This was followed by semistructured individual interviews with a subgroup of purposefully sampled IAPT practitioners (n = 32) to explore in greater depth those topics identified from the survey responses that warranted further enquiry. Qualitative data were analysed using a realist inquiry approach into which the descriptive statistical results of the survey were included (objective 3).

Translation and validation of the EQ-5D-5L version in British Sign Language

A five-stage translation protocol in collaboration with assessment originators, including forward/back translation with independent translation teams and respondent testing resulting in a final fourth draft for testing with a general population self-selecting sample of Deaf BSL users (n = 92) hosted via an online secure portal. Participants completed a short demographic survey and the BSL versions of the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), Clinical Outcomes in Routine Evaluation – 10-item version (CORE-10) BSL and Clinical Outcomes in Routine Evaluation – 6-item version (CORE-6D) BSL through the online platform. They were asked to take part in the retest of the EQ-5D-5L BSL approximately 1 week later and 74 did so. A sample size of 51 allows a 95% confidence interval for an intraclass correlation coefficient of 0.75 to be estimated to within ± 0.1. The psychometric properties of the EQ-5D-5L BSL were examined. The analyses included content validity (assessed by interviewing a small sample of Deaf people); internal consistency of the items and test–retest were assessed for its reliability (using Cronbach’s alpha values and weighted kappa scores); and convergent validity was assessed by determining how well EQ-5D-5L BSL correlates with CORE-10 BSL and CORE-6D BSL (using Kendall’s tau coefficient) (objectives 1 and 2).

Calculating utility values for the Deaf population

Descriptive statistics were used to summarise the responses of Deaf people to the population norms for the EuroQol-5 Dimensions (EQ-5D) domains (per cent reporting no problems) and EQ-5D utility weights [mean, standard deviation (SD)] and to compare these to population norms. Deaf participants’ (n = 92) EQ-5D-5L scores and utility values were compared with published norms from the hearing population, identified via the EuroQol website. Linear regression was used to establish whether or not participants’
sociodemographic characteristics were associated with Deaf participants' health and EQ-5D-5L utility weights. The analysis was also used, with descriptive statistics used to assess whether or not utility values differed between people with and without depression. In line with clinical cut-off points from the hearing population, a CORE-10 score of ≥ 13 was used to identify participants with and without depression (note that cut-off values specific to the Deaf population are not available) (objectives 1 and 2).

**Exploratory economic evaluation**

The economic evaluation used a two-part economic model to synthesise data from the IAPT databases and published literature. The overall perspective or decision-maker viewpoint used to determine the range of costs is that of health and social care providers. The economic model focuses on Deaf BSL adults referred to IAPT for a low- or high-intensity intervention to treat depression and/or anxiety. The intervention is the BSL-IAPT specialist service, which is compared with standard IAPT services. The economic model estimates the costs and quality-adjusted life-years (QALYs) for 1 year after a person’s first contact with the service. Depression and anxiety are long-term conditions, so the economic model also explored the costs and QALYs over longer time periods. The price year is 2015 and costs are presented in UK pounds sterling (£).

**Results**

**The acceptability of randomisation and trial-related terminology in British Sign Language**

The four main influences on the acceptability of randomisation were (1) whether or not participation would benefit Deaf people as a whole, rather than the individual per se; (2) whether or not, if perceived as another example of imposed choice in Deaf people’s lives, it would be resisted; (3) whether or not it implies that linguistic needs will not be met or respected; and (4) if it implicitly or explicitly denies the value of Deaf people’s points of view and life experiences.

**The clinical cut-off points for the Patient Health Questionnaire-9 items in British Sign Language and Generalised Anxiety Disorder-7 in British Sign Language**

The clinical cut-off points for the PHQ-9 in BSL and GAD-7 in BSL are 8 and 6, respectively. This compares with the original English version cut-off points in the hearing population of 10 and 8, respectively, meaning that a lower score is required to reach caseness in the BSL versions of the assessments. The three different statistical choices for calculating clinical cut-off points (equalising, maximising and prioritising false-negative to false-positive ratio of ≈ 1 : 2) all showed a lower clinical cut-off point for the Deaf population with respect to the PHQ-9 BSL and GAD-7 BSL, with the exception of the maximising criteria when used with the PHQ-9 BSL. The primary limitation on this result is that the design did not include a gold standard clinical interview.

**Comparison of Deaf users of BSL-IAPT and standard Improving Access to Psychological Therapies characteristics and clinical outcomes**

There was no significant difference between Deaf clients of standard IAPT and BSL-IAPT in reliable improvement (63.5% vs. 66.8%; p = 0.917) and no difference in reliable recovery (40.0% vs. 40.4%; p = 0.946), based on attending a minimum of two therapeutic appointments as the definition of treatment completion. Using the tighter definition of completed therapy, reliable improvement in Deaf clients attending BSL-IAPT services was 76.5%, whereas reliable recovery was 54.0%. These results compare favourably with recent national IAPT statistics, which report reliable improvement as 61.5% and reliable recovery as 43.1%. However, the results should be treated with considerable caution because of the small number of Deaf users of standard IAPT on which they are based (n = 89) and small number of standard IAPT services (n = 21), most of which had seen fewer than four Deaf clients.

**Mixed-methods modelling of standard Improving Access to Psychological Therapies services accessed by Deaf people and BSL-IAPT**

Problematic issues in standard IAPT provision for Deaf people included self-referral and general access arrangements that were heavily biased towards use of written English; little understanding of the impact of
interpreter use on the therapeutic encounter; lack of use of the IAPT assessments in BSL; a poor background understanding of Deaf clients' knowledge needs in order to engage in therapy; low cultural competence; and lack of robust systems of equality impact monitoring. Key components of BSL-IAPT included direct rather than indirect therapeutic experience; the cultural and linguistic compatibility of the therapist; the choice of therapist; structural components that supported a culture of quality improvement and monitoring in meeting Deaf clients requirements; and boundary issues arising from Deaf community members in multiple roles.

**Translation and validation of the EQ-5D-5L version in British Sign Language**

The psychometric properties of the EQ-5D-5L BSL are good, indicating that it can be used to measure health status in the Deaf signing population in the UK. Convergent validity between EQ-5D-5L BSL and CORE-10 BSL and CORE-6D BSL is consistent, demonstrating that the BSL version of EQ-5D-5L is a good measure of an individual's health status. The test–retest reliability of EQ-5D-5L BSL, for each dimension of health, was shown to have Cohen's kappa values of 0.47–0.61; these were in the range of moderate to good and were, therefore, acceptable. This is the first time that EQ-5D-5L has been translated into a signed language for use with Deaf people and validated, and is a significant step forward in conducting studies of health status and cost-effectiveness in this population.

**Utility values and the Deaf population**

The mean utility value was 0.77 (SD 0.03; n = 82) for Deaf study participants, which is lower than the published UK population norm (0.86, SD 0.23; n = 3392). The results indicate that health status and associated utility norms published for the general population may not be generalisable to the Deaf population. The mean utility in this group was nearly 10% lower than the general population published norms. In addition, depression and anxiety are shown to be more prevalent in this group. Statistical analysis indicated that, as may be expected, utility values for Deaf people with depression may be lower than for people without depression. Our results provide EQ-5D-5L utility values relevant to a Deaf population, which have previously been unavailable. However, there are some limitations. In particular, the study sample (n = 92 overall; n = 82 with complete utility data) is too small to draw strong conclusions.

**Exploratory economic evaluation**

BSL-IAPT is associated with a net saving of £240 (SD £832; 2.5th percentile −£2303, 97.5th percentile £935). However, the 95th percentiles cross zero, indicating uncertainty about whether BSL-IAPT is associated with a net saving or net cost. The model predicts that BSL-IAPT services are associated with a very small gain of 0.001 QALYs. Again, the 95th percentiles cross zero, indicating uncertainty about whether BSL-IAPT is associated with a QALY gain or loss. The cost-effectiveness acceptability analysis suggests that there is a 57% probability that BSL-IAPT is cost-effective if decision-makers are willing to pay £20,000 to gain a single QALY. Most of the sensitivity analyses indicated that BSL-IAPT was likely to be cost-effective. Two exceptions were, first, if the costs of an interpreter were excluded from the costs of the standard IAPT service, BSL-IAPT was not likely to be cost-effective, and, second, if the range of services provided by BSL-IAPT included more high-intensity treatment, standard IAPT was more likely to be cost-effective than BSL-IAPT. However, there were limited data and a high level of variance and uncertainty in the estimates of the costs and QALYs associated with the two services.

**Conclusions**

This study has provided the first evidence of the acceptability of randomisation and exploration of trial-related terminology to be published with respect to sign language users anywhere in the world. It has established, for the first time, clinical cut-off points for translated/validated standard instruments in BSL in clinical use in the UK with Deaf people. It has produced the first comparative outcome data on Deaf users of IAPT services (whether standard or BSL-IAPT services), including reporting the largest verified clinical data set on Deaf people with anxiety and/or depression in the UK. It has established the first ever validated version of the EQ-5D-5L in any sign language in the world and reported its operational
characteristics. It has demonstrated that the health status and associated utility norms published for the
general population may not be generalisable to the Deaf population.

However, the feasibility of recruiting sufficiently large numbers to any future large-scale study of effectiveness
and cost-effectiveness of BSL-IAPT versus standard IAPT is yet to be tested, and clinical data recording in its
current form has been shown to be unreliable. Small numbers have meant that the evidence base comparing
reliable recovery and reliable improvement for Deaf users of BSL-IAPT and standard IAPT is weak and it is not
possible to produce good estimates of effect size.

A carefully controlled large-scale prospective observational study would enable greater recruitment of
target population numbers, control of consistency and validity of clinical data recording and specification
and standardisation of components of the delivery of an intervention to Deaf people within either BSL-IAPT
or standard IAPT delivery structures. It would also enable investigation of the determinants of reliable
recovery and reliable improvement in the Deaf clinical population in comparison with existing knowledge
about the general population users of IAPT services. A larger prospective cohort study would also help to
inform those sociodemographic and clinical characteristics that are key influencers of utility, which would
allow us to more fully investigate utility in the Deaf BSL population.

Finally, there is a dearth of epidemiological evidence on the Deaf population, which severely hampers
health research; therefore, some consideration should be given to establishing a Deaf mental health
observatory in the UK, which would benefit many studies in the future.

**Funding**

Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
Criteria for inclusion in the Health Services and Delivery Research journal
Reports are published in Health Services and Delivery Research (HS&DR) if (1) they have resulted from work for the HS&DR programme or programmes which preceded the HS&DR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

HS&DR programme
The Health Services and Delivery Research (HS&DR) programme, part of the National Institute for Health Research (NIHR), was established to fund a broad range of research. It combines the strengths and contributions of two previous NIHR research programmes: the Health Services Research (HSR) programme and the Service Delivery and Organisation (SDO) programme, which were merged in January 2012.

The HS&DR programme aims to produce rigorous and relevant evidence on the quality, access and organisation of health services including costs and outcomes, as well as research on implementation. The programme will enhance the strategic focus on research that matters to the NHS and is keen to support ambitious evaluative research to improve health services.

For more information about the HS&DR programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hsdr

This report
The research reported in this issue of the journal was funded by the HS&DR programme or one of its preceding programmes as project number 12/136/79. The contractual start date was in April 2014. The final report began editorial review in October 2016 and was accepted for publication in March 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HS&DR editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HS&DR programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HS&DR programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Young et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
**Health Services and Delivery Research Editor-in-Chief**

Professor Jo Rycroft-Malone  Professor of Health Services and Implementation Research, Bangor University, UK

**NIHR Journals Library Editor-in-Chief**

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

**NIHR Journals Library Editors**

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:**  journals.library@nihr.ac.uk